Business Context and Reporting Period
This Form 8-K is a current report filed by Magenta Therapeutics, Inc. (not Dianthus Therapeutics, Inc.) on June 1, 2021. The filing covers events occurring on June 1, 2021, specifically the resignation of a director and the results of the Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance.
Material Changes
- Board Resignation: Blake Byers, Ph.D., resigned from the Board of Directors and the Nominating and Corporate Governance Committee effective June 1, 2021. The resignation was not due to any dispute with the Company.
- Director Elections: Stockholders elected four Class III directors (Bruce Booth, Thomas O. Daniel, Jason Gardner, and Alison F. Lawton) to three-year terms ending in 2024.
- Accounting Firm Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. It strictly reports on the outcomes of the Annual Meeting and the departure of a director.
Investor Verification Checklist
- Verify the correct registrant name is Magenta Therapeutics, Inc. (Ticker: MGTA), as the input metadata incorrectly listed Dianthus Therapeutics.
- Confirm the voting results for the four newly elected Class III directors, noting the significant number of broker non-votes (13,613,689) for each director.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 21, 2021) for detailed background on the director nominees and the ratification of KPMG LLP.
- Check subsequent filings to determine if a replacement director was appointed to fill the vacancy left by Dr. Byers.